Journal of the National Medical Association · 2025
Efficacy of SGLT2 inhibitors on acute kidney injury in patients with chronic kidney disease, cardiovascular disease, and type 2 diabetes: A meta-analysis.
СтатьяМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dong Zhiyuan, Mo Wenqing, Ling Zhougui, Hou Luqi, Deng Tingting
Аннотация
OBJECTIVE: To evaluate the efficacy of sodium-glucose cotransporter-2 (SGLT2) inhibitors in reducing the risk of acute kidney injury (AKI) in patients with chronic kidney disease (CKD), cardiovascular disease (CVD), and type 2 diabetes mellitus (T2DM).
METHODS: A meta-analysis were conducted on the randomized controlled trials (RCTs) comparing SGLT2 inhibitors with placebo in the incidence of AKI. Databases were searched for relevant studies up to September 23, 2024. The primary outcome was the occurrence of AKI.
RESULTS: There are 8 studies ultimately met the inclusion criteria. These studies encompassed a total of 65,606 patients, with 1,853 cases of AKI reported. The analysis demonstrated that SGLT2 inhibitors significantly reduced the risk of AKI compared to placebo (HR 0.78, CI 0.71-0.85, P < 0.001). In addition, subgroup analysis revealed that SGLT2 inhibitors effectively lowered the risk of AKI in patients with initial eGFR ≥ 60 mL/min/1.73 m² (HR 0.61, CI 0.42-0.88, P < 0.01) and eGFR < 60 mL/min/1.73 m² (HR 0.74, CI 0.58-0.94, P < 0.05). However, in patients with eGFR < 45 mL/min/1.73 m², there was no significant difference in AKI incidence between the SGLT2 inhibitor group and the placebo group (HR 1.04, CI 0.50-2.17, P = 0.91). In white or Asian patients, there was no significant difference in AKI incidence between the SGLT2 inhibitor group and the placebo group (0.75, CI 0.48-1.17, P = 0.21) and (0.97, CI 0.26-3.70, P = 0.96).
CONCLUSION: SGLT2 inhibitors significantly reduce the risk of AKI in patients with CKD, CVD, and T2DM, with greater efficacy observed in those with higher initial eGFR. However, when eGFR falls below 45 mL/min/1.73 m², SGLT2 inhibitors do not reduce the occurrence of AKI.
METHODS: A meta-analysis were conducted on the randomized controlled trials (RCTs) comparing SGLT2 inhibitors with placebo in the incidence of AKI. Databases were searched for relevant studies up to September 23, 2024. The primary outcome was the occurrence of AKI.
RESULTS: There are 8 studies ultimately met the inclusion criteria. These studies encompassed a total of 65,606 patients, with 1,853 cases of AKI reported. The analysis demonstrated that SGLT2 inhibitors significantly reduced the risk of AKI compared to placebo (HR 0.78, CI 0.71-0.85, P < 0.001). In addition, subgroup analysis revealed that SGLT2 inhibitors effectively lowered the risk of AKI in patients with initial eGFR ≥ 60 mL/min/1.73 m² (HR 0.61, CI 0.42-0.88, P < 0.01) and eGFR < 60 mL/min/1.73 m² (HR 0.74, CI 0.58-0.94, P < 0.05). However, in patients with eGFR < 45 mL/min/1.73 m², there was no significant difference in AKI incidence between the SGLT2 inhibitor group and the placebo group (HR 1.04, CI 0.50-2.17, P = 0.91). In white or Asian patients, there was no significant difference in AKI incidence between the SGLT2 inhibitor group and the placebo group (0.75, CI 0.48-1.17, P = 0.21) and (0.97, CI 0.26-3.70, P = 0.96).
CONCLUSION: SGLT2 inhibitors significantly reduce the risk of AKI in patients with CKD, CVD, and T2DM, with greater efficacy observed in those with higher initial eGFR. However, when eGFR falls below 45 mL/min/1.73 m², SGLT2 inhibitors do not reduce the occurrence of AKI.